Abstract
Erectile dysfunction (ED) has multifactor pathogenesis, with neurological, vascular, endocrinological and psychogenic components described. However, about 50-85% of ED population report the presence of one or more comorbidities i.e. hypertension, diabetes, cardiovascular disease, dyslipidemia which all impair endothelial function and, erection is a basically vascular event that necessitates an intact endothelium to occur. Hence, ED may be mostly considered as the clinical manifestation of a disease affecting penile circulation as a part of a generalized vascular disorder due to atherosclerosis. Orally active drugs, i.e. phosphodiesterase type-5 inhibitors (PDE5-i), are a group of on-demand drugs licensed for ED treatment and appear to offer advantages over past therapies in terms of ease of administration and cost, and they are now widely advocated as first-line therapy. The recent discovery that chronic not on-demand administration of these drugs may improve erectile and endothelial response in men previously unresponding to on-demand regimes, opens a new scenario in the treatment of men with ED and comorbidities. Finally, the recent approval of PDE5-i sildenafil for the treatment of pulmonary arterial hypertension represents the new challenge for these class of drugs. Aim of this article will be to provide an update on the pathophysiology of ED and how to use of different available PDE5-i in approaching sexual dysfunctional men, pointing out on their characteristic of efficacy and safety and different indications in special subpopulations.
Keywords: Phosphodiesterase 5 inhibitors, Erection, Cardiovascular disease, Endothelium, Efficacy, Safety
Current Pharmaceutical Design
Title: Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Volume: 12 Issue: 27
Author(s): Antonio Aversa, Roberto Bruzziches, Marcello Pili and Giovanni Spera
Affiliation:
Keywords: Phosphodiesterase 5 inhibitors, Erection, Cardiovascular disease, Endothelium, Efficacy, Safety
Abstract: Erectile dysfunction (ED) has multifactor pathogenesis, with neurological, vascular, endocrinological and psychogenic components described. However, about 50-85% of ED population report the presence of one or more comorbidities i.e. hypertension, diabetes, cardiovascular disease, dyslipidemia which all impair endothelial function and, erection is a basically vascular event that necessitates an intact endothelium to occur. Hence, ED may be mostly considered as the clinical manifestation of a disease affecting penile circulation as a part of a generalized vascular disorder due to atherosclerosis. Orally active drugs, i.e. phosphodiesterase type-5 inhibitors (PDE5-i), are a group of on-demand drugs licensed for ED treatment and appear to offer advantages over past therapies in terms of ease of administration and cost, and they are now widely advocated as first-line therapy. The recent discovery that chronic not on-demand administration of these drugs may improve erectile and endothelial response in men previously unresponding to on-demand regimes, opens a new scenario in the treatment of men with ED and comorbidities. Finally, the recent approval of PDE5-i sildenafil for the treatment of pulmonary arterial hypertension represents the new challenge for these class of drugs. Aim of this article will be to provide an update on the pathophysiology of ED and how to use of different available PDE5-i in approaching sexual dysfunctional men, pointing out on their characteristic of efficacy and safety and different indications in special subpopulations.
Export Options
About this article
Cite this article as:
Aversa Antonio, Bruzziches Roberto, Pili Marcello and Spera Giovanni, Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction, Current Pharmaceutical Design 2006; 12 (27) . https://dx.doi.org/10.2174/138161206778343046
DOI https://dx.doi.org/10.2174/138161206778343046 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Renal Complications of Fabry Disease
Current Pharmaceutical Design Pharmacokinetic and Pharmacodynamic Studies of Nifedipine Loaded Microspheres for the Treatment of Hypertension
Current Drug Delivery p66 Shc as the Engine of Vascular Aging
Current Vascular Pharmacology Tolerability of Amine Uptake Inhibitors in Urologic Diseases
Current Drug Safety Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
Current Molecular Medicine Recent Patents on Ocular Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates
Current Medicinal Chemistry Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery How to Investigate the Vascular Changes in Resistant Hypertension
Current Hypertension Reviews Neurovascular Role of Sympathetic Nervous System and Beta-Adrenoceptor Polymorphisms in Obesity and Hypertension
Current Hypertension Reviews Bivalent Ligands for G Protein-Coupled Receptors
Current Pharmaceutical Design Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology The Effects of Soy Isoflavones in Postmenopausal Women: Clinical Review
Current Drug Therapy Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design The Use of Plant Sterols and Stanols as Lipid-Lowering Agents in Cardiovascular Disease
Current Pharmaceutical Design Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
Current Cardiology Reviews Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of PDE5-Inhibitors in Cardiopulmonary Disorders: From Basic Evidence to Clinical Development
Current Medicinal Chemistry The Role of Neuropeptide Y and Peptide YY in the Development of Obesity via Gut-brain Axis
Current Protein & Peptide Science